| N-Terminal domain antiandrogen | |
|---|---|
| Drug class | |
 EPI-001, the first major N-terminal domain AR antagonist to be developed. | |
| Class identifiers | |
| Synonyms | N-Terminal domain AR antagonists; AR NTD antagonists |
| Use | Prostate cancer |
| Biological target | Androgen receptor |
| Legal status | |
| In Wikidata | |
N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.